Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Natural Killer Cells in Cancer Immunotherapy
Jeffrey S. Miller, Lewis L. Lanier
Annual Review of Cancer Biology (2018) Vol. 3, Iss. 1, pp. 77-103
Open Access | Times Cited: 133

Showing 1-25 of 133 citing articles:

Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Karthik Dhatchinamoorthy, Jeff D. Colbert, Kenneth L. Rock
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 698
Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19
Yapeng Su, Daniel Chen, Dan Yuan, et al.
Cell (2020) Vol. 183, Iss. 6, pp. 1479-1495.e20
Open Access | Times Cited: 558
Lipid metabolism in cancer: New perspectives and emerging mechanisms
Lindsay A. Broadfield, Antonino Alejandro Pane, Ali Talebi, et al.
Developmental Cell (2021) Vol. 56, Iss. 10, pp. 1363-1393
Open Access | Times Cited: 425
Plasticity of innate lymphoid cell subsets
Suzanne M. Bal, Korneliusz Golebski, Hergen Spits
Nature reviews. Immunology (2020) Vol. 20, Iss. 9, pp. 552-565
Closed Access | Times Cited: 251
Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity
Zhu Huang, Robert Blum, Davide Bernareggi, et al.
Cell stem cell (2020) Vol. 27, Iss. 2, pp. 224-237.e6
Open Access | Times Cited: 246
Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity
Zhu Huang, Robert Blum, Ryan Bjordahl, et al.
Blood (2019) Vol. 135, Iss. 6, pp. 399-410
Open Access | Times Cited: 214
An expanded universe of cancer targets
William C. Hahn, Joel S. Bader, Theodore P. Braun, et al.
Cell (2021) Vol. 184, Iss. 5, pp. 1142-1155
Open Access | Times Cited: 182
CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy
Michael C. Burger, Congcong Zhang, Patrick N. Harter, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 178
TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
Zhouhong Ge, Maikel P. Peppelenbosch, Dave Sprengers, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 162
Human immunology and immunotherapy: main achievements and challenges
Jezabel Varadé, Susana Magadán, África González‐Fernández
Cellular and Molecular Immunology (2020) Vol. 18, Iss. 4, pp. 805-828
Open Access | Times Cited: 156
Natural Killer Cells: From Innate to Adaptive Features
Adriana M. Mujal, Rebecca B. Delconte, Joseph C. Sun
Annual Review of Immunology (2021) Vol. 39, Iss. 1, pp. 417-447
Open Access | Times Cited: 138
Natural killer cell engagers in cancer immunotherapy: Next generation of immuno‐oncology treatments
Olivier Demaria, Laurent Gauthier, Guilhaume Debroas, et al.
European Journal of Immunology (2021) Vol. 51, Iss. 8, pp. 1934-1942
Closed Access | Times Cited: 116
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies
Nina Lamers-Kok, Denise Panella, Anna‐Maria Georgoudaki, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 102
iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting
Benjamin Goldenson, Pooja Hor, Dan S. Kaufman
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 88
Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy
Reza Hosseini, Hamzeh Sarvnaz, Maedeh Arabpour, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 78
When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer
Mohamed S. Hasim, Marie Marotel, Jonathan J. Hodgins, et al.
Science Advances (2022) Vol. 8, Iss. 15
Open Access | Times Cited: 73
Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma
Michael C. Burger, Marie-Thérèse Forster, A Romański, et al.
Neuro-Oncology (2023) Vol. 25, Iss. 11, pp. 2058-2071
Open Access | Times Cited: 52
Metabolic Modulation of Immunity: A New Concept in Cancer Immunotherapy
Luana Guerra, Lynn Bonetti, Dirk Brenner
Cell Reports (2020) Vol. 32, Iss. 1, pp. 107848-107848
Open Access | Times Cited: 133
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Yuqing Cao, Xiaoyu Wang, Tianqiang Jin, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 122
The Immunology of Hormone Receptor Positive Breast Cancer
Jonathan M. Goldberg, Ricardo Pastorello, Tuulia Vallius, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 100
TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer
Karen Slattery, Elena Woods, Vanessa Zaiatz-Bittencourt, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 2, pp. e002044-e002044
Open Access | Times Cited: 98
Targeting Innate Immunity in Cancer Therapy
Srikrishnan Rameshbabu, Brian Labadie, Anna Argulian, et al.
Vaccines (2021) Vol. 9, Iss. 2, pp. 138-138
Open Access | Times Cited: 96
CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma
Kyle B. Lupo, Sandro Matosevic
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 83
Lifting the innate immune barriers to antitumor immunity
Carla V. Rothlin, Sourav Ghosh
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000695-e000695
Open Access | Times Cited: 73
Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells
Kate Dixon, Jianming Wu, Bruce Walcheck
Cancers (2021) Vol. 13, Iss. 2, pp. 312-312
Open Access | Times Cited: 67
Page 1 - Next Page

Scroll to top